Rodney Evan Fuller

Array ( [id] => 18903011 [patent_doc_number] => 20240018496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => Compositions and Methods for Kallikrein (KLKB1) Gene Editing [patent_app_type] => utility [patent_app_number] => 18/362675 [patent_app_country] => US [patent_app_date] => 2023-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18362675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17897377 [patent_doc_number] => 20220307039 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => CODON-OPTIMIZED NUCLEOTIDE SEQUENCES ENCODING AN AP-1 TRANSCRIPTION FACTOR [patent_app_type] => utility [patent_app_number] => 17/679977 [patent_app_country] => US [patent_app_date] => 2022-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30725 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17679977 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18242424 [patent_doc_number] => 20230074735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => METAL ION-START DNA POLYMERASE SWITCH AND ISOTHERMAL POLYMERASE AMPLIFICATION METHOD USING THE SAME [patent_app_type] => utility [patent_app_number] => 17/675229 [patent_app_country] => US [patent_app_date] => 2022-02-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6027 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17675229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17759964 [patent_doc_number] => 20220233576 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => SOLUTE CARRIER FAMILY 46 MEMBER 3 (SLC46A3) AS MARKER FOR LIPID-BASED NANOPARTICLE CANCER THERAPY AND DIAGNOSTICS [patent_app_type] => utility [patent_app_number] => 17/582594 [patent_app_country] => US [patent_app_date] => 2022-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16901 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17582594 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17052527 [patent_doc_number] => 20210261961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-26 [patent_title] => ANTISENSE OLIGONUCLEOTIDES TARGETING TIA1 [patent_app_type] => utility [patent_app_number] => 17/245443 [patent_app_country] => US [patent_app_date] => 2021-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17245443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200435 [patent_doc_number] => 20210340530 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => Compositions and Methods for Immunotherapy [patent_app_type] => utility [patent_app_number] => 17/231556 [patent_app_country] => US [patent_app_date] => 2021-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46519 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17231556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17258876 [patent_doc_number] => 20210371861 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => Multi-Targeting Nucleic Acid Constructs Composed Of Multiple Oligonucleotides That Modulate Gene Expression Through Complimentary Interactions With Targets [patent_app_type] => utility [patent_app_number] => 17/215964 [patent_app_country] => US [patent_app_date] => 2021-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8440 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17215964 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16977936 [patent_doc_number] => 20210222173 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene Editing [patent_app_type] => utility [patent_app_number] => 17/212901 [patent_app_country] => US [patent_app_date] => 2021-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39542 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -193 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17212901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299896 [patent_doc_number] => 20210395735 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/204008 [patent_app_country] => US [patent_app_date] => 2021-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11422 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17204008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17183928 [patent_doc_number] => 20210330813 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => RNAI INDUCED C9ORF72 SUPPRESSION FOR THE TREATMENT OF ALS/FTD [patent_app_type] => utility [patent_app_number] => 17/196531 [patent_app_country] => US [patent_app_date] => 2021-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17196531 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17946104 [patent_doc_number] => 20220333121 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => TRANSLATION ENHANCER, TEMPLATE NUCLEIC ACID, PRODUCTION METHOD OF TRANSLATION TEMPLATE, AND PRODUCTION METHOD OF PROTEIN [patent_app_type] => utility [patent_app_number] => 17/269186 [patent_app_country] => US [patent_app_date] => 2020-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6220 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17269186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399921 [patent_doc_number] => 20220042011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => ANTISENSE OLIGONUCLEOTIDES TARGETING CARD9 [patent_app_type] => utility [patent_app_number] => 17/311175 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17311175 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17357110 [patent_doc_number] => 20220017906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/312721 [patent_app_country] => US [patent_app_date] => 2019-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45274 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312721 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17414348 [patent_doc_number] => 20220049252 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/312383 [patent_app_country] => US [patent_app_date] => 2019-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32470 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -67 [patent_words_short_claim] => 225 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312383 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17355359 [patent_doc_number] => 20220016155 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => Composition for Inhibiting Replication of Hepatitis B Virus [patent_app_type] => utility [patent_app_number] => 17/294171 [patent_app_country] => US [patent_app_date] => 2019-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5164 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17294171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17733277 [patent_doc_number] => 20220218736 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => NEW THERAPY [patent_app_type] => utility [patent_app_number] => 17/290582 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13746 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17444135 [patent_doc_number] => 20220064640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => DOUBLE-STRANDED NUCLEIC ACID INHIBITOR MOLECULES CONTAINING A TRILOOP [patent_app_type] => utility [patent_app_number] => 17/311949 [patent_app_country] => US [patent_app_date] => 2019-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19257 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17311949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200473 [patent_doc_number] => 20210340568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => REGULATED GENE EDITING SYSTEM [patent_app_type] => utility [patent_app_number] => 17/283322 [patent_app_country] => US [patent_app_date] => 2019-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33392 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283322 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17228937 [patent_doc_number] => 20210355493 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => OLIGONUCLEOTIDE MEDIATED NO-GO DECAY [patent_app_type] => utility [patent_app_number] => 17/282340 [patent_app_country] => US [patent_app_date] => 2019-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19539 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -81 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17282340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18194491 [patent_doc_number] => 20230048010 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATION [patent_app_type] => utility [patent_app_number] => 17/280384 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 80761 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17280384 [rel_patent_id] =>[rel_patent_doc_number] =>)